<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">11480571</PMID>
<DateCompleted>
<Year>2001</Year>
<Month>08</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0887-6924</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>15</Volume>
<Issue>8</Issue>
<PubDate>
<Year>2001</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Leukemia</Title>
<ISOAbbreviation>Leukemia</ISOAbbreviation>
</Journal>
<ArticleTitle>Thalidomide for previously untreated indolent or smoldering multiple myeloma.</ArticleTitle>
<Pagination>
<MedlinePgn>1274-6</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>We conducted a clinical trial of thalidomide as initial therapy for asymptomatic smoldering (SMM) or indolent multiple myeloma (IMM). Sixteen patients were studied. Thalidomide was given orally at a dose of 200 mg/day for 2 weeks, and then increased as tolerated by 200 mg/day every 2 weeks to a maximum dose of 800 mg/day. Bone marrow microvessel density (MVD) and angiogenesis grading were estimated using CD34 immunostaining. Six patients had a confirmed response to therapy with at least 50% or greater reduction in serum and urine monoclonal (M) protein. When minor responses (25-49%) decrease in M protein concentration) were included, 11 of 16 patients (69%) responded to therapy. Major grade 3-4 toxicities included two patients with somnolence, and one patient each with syncope and neutropenia. Pre-treatment MVD was not a significant predictor of response to therapy, median MVD 4 and 12 in responders and non-responders respectively, P = 0.09. We conclude that thalidomide has significant activity in the treatment of newly diagnosed SMM/IMM. However, we do not recommend treatment with thalidomide at this stage since some patients with SMM/IMM can be stable for several months or years without any therapy. Additional randomized trials are needed to determine if thalidomide will delay progression to active multiple myeloma.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Rajkumar</LastName>
<ForeName>S V</ForeName>
<Initials>SV</Initials>
<AffiliationInfo>
<Affiliation>Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dispenzieri</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fonseca</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lacy</LastName>
<ForeName>M Q</ForeName>
<Initials>MQ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Geyer</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lust</LastName>
<ForeName>J A</ForeName>
<Initials>JA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kyle</LastName>
<ForeName>R A</ForeName>
<Initials>RA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Greipp</LastName>
<ForeName>P R</ForeName>
<Initials>PR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gertz</LastName>
<ForeName>M A</ForeName>
<Initials>MA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Witzig</LastName>
<ForeName>T E</ForeName>
<Initials>TE</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>CA62242</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA85818</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Leukemia</MedlineTA>
<NlmUniqueID>8704895</NlmUniqueID>
<ISSNLinking>0887-6924</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>4Z8R6ORS6L</RegistryNumber>
<NameOfSubstance UI="D013792">Thalidomide</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000284">Administration, Oral</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020533">Angiogenesis Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009101">Multiple Myeloma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013792">Thalidomide</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>2001</Year>
<Month>8</Month>
<Day>2</Day>
<Hour>10</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2001</Year>
<Month>8</Month>
<Day>17</Day>
<Hour>10</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2001</Year>
<Month>8</Month>
<Day>2</Day>
<Hour>10</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">11480571</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>